Retatrutide and trizepatide are a new class of medications that target both the glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. These combined receptor agonists https://craiglcpu722893.ka-blogs.com/91905894/recent-glp-1-and-gip-receptor-agonists-retatrutide-and-trizepatide